Background
Methods
Data source
Study population
Outcome measures
Statistical analysis
Results
Patient disposition
Overall | Raloxifene subgroup | |||||||
---|---|---|---|---|---|---|---|---|
Characteristic | All (N = 15,559) | T2DM (N = 7580) | Non-DM (N = 7979) | P value | All (N = 1367) | T2DM (N = 668) | Non-DM (N = 699) | P value |
Age in years, mean (SD) | 73.1 (9.10) | 73.4 (8.99) | 72.9 (9.19) | <0.001 | 73.7 (9.08) | 74.9 (8.45) | 72.6 (9.53) | <0.001 |
Age, n (%) | <0.001 | <0.001 | ||||||
50–54 years | 439 (2.8) | 203 (2.7) | 236 (3.0) | 35 (2.6) | 8 (1.2) | 27 (3.9) | ||
55–59 years | 896 (5.8) | 413 (5.4) | 483 (6.1) | 62 (4.5) | 22 (3.3) | 40 (5.7) | ||
60–64 years | 1515 (9.7) | 679 (9.0) | 836 (10.5) | 114 (8.3) | 40 (6.0) | 74 (10.6) | ||
65–69 years | 2309 (14.8) | 1064 (14.0) | 1245 (15.6) | 229 (16.8) | 103 (15.4) | 126 (18.0) | ||
70–74 years | 2967 (19.1) | 1504 (19.8) | 1463 (18.3) | 264 (19.3) | 144 (21.6) | 120 (17.2) | ||
75–79 years | 3406 (21.9) | 1695 (22.4) | 1711 (21.4) | 280 (20.5) | 145 (21.7) | 135 (19.3) | ||
80 years and older | 4027 (25.9) | 2022 (26.7) | 2005 (25.1) | 383 (28.0) | 206 (30.8) | 177 (25.3) | ||
Fractures, n (%) | ||||||||
Patients with clinical fracturesa | 810 (5.2) | 405 (5.3) | 405 (5.1) | 0.453 | 76 (5.6) | 45 (6.7) | 31 (4.4) | 0.063 |
Patients with non-vertebral fractures | 542 (3.5) | 275 (3.6) | 267 (3.3) | 0.338 | 62 (4.5) | 33 (4.9) | 29 (4.1) | 0.482 |
Charlson Comorbidity Index, mean (SD) | 2.15 (2.28) | 2.76 (2.37) | 1.58 (2.03) | <0.001 | 1.70 (1.87) | 2.30 (1.99) | 1.13 (1.55) | <0.001 |
Comorbidities, n (%) | ||||||||
Dyslipidemia | 5329 (34.3) | 3671 (48.4) | 1658 (20.8) | <0.001 | 429 (31.4) | 323 (48.4) | 106 (15.2) | <0.001 |
Arteriosclerosis | 1487 (9.6) | 935 (12.3) | 552 (6.9) | <0.001 | 112 (8.2) | 75 (11.2) | 37 (5.3) | <0.001 |
Peripheral vascular disease | 1926 (12.4) | 1178 (15.5) | 748 (9.4) | <0.001 | 164 (12.0) | 96 (14.4) | 68 (9.7) | 0.008 |
Thyroid disease | 1702 (10.9) | 1120 (14.8) | 582 (7.3) | <0.001 | 138 (10.1) | 93 (13.9) | 45 (6.4) | <0.001 |
Liver disease | 2817 (18.1) | 1914 (25.3) | 903 (11.3) | <0.001 | 212 (15.5) | 155 (23.2) | 57 (8.2) | <0.001 |
Chronic kidney disease | 823 (5.3) | 647 (8.5) | 176 (2.2) | <0.001 | 57 (4.2) | 49 (7.3) | 8 (1.1) | <0.001 |
Type 2 diabetes | 4580 (29.4) | 4580 (60.4) | - | <0.001 | 357 (26.1) | 357 (53.4) | - | <0.001 |
Osteoporosis medications initiated, n (%) | ||||||||
Bisphosphonates | 8913 (57.3) | 4140 (54.6) | 4773 (59.8) | <0.001 | 47 (3.4) | 18 (2.7) | 29 (4.1) | 0.140 |
SERMs | 1373 (8.8) | 670 (8.8) | 703 (8.8) | 0.950 | 1367 (100.0) | 668 (100.0) | 699 (100.0) | - |
Active vitamin Db | 6155 (39.6) | 3101 (40.9) | 3054 (38.3) | <0.001 | 385 (28.2) | 167 (25.0) | 218 (31.2) | 0.011 |
Calcitonin | 4 (0.0) | 1 (0.0) | 3 (0.0) | 0.343c | - | - | - | |
Raloxifene without alendronate | 1339 (8.6) | 660 (8.7) | 679 (8.5) | 0.661 | 1339 (98.0) | 660 (98.8) | 679 (97.1) | 0.030 |
Raloxifene and alendronate in combination | 28 (0.2) | 8 (0.1) | 20 (0.3) | 0.033 | 28 (2.0) | 8 (1.2) | 20 (2.9) | 0.030 |
Alendronate without raloxifene | 5363 (34.5) | 2476 (32.7) | 2887 (36.2) | <0.001 | - | - | - | - |
Other medications, n (%) | ||||||||
Corticosteroid | 3020 (19.4) | 1910 (25.2) | 1110 (13.9) | <0.001 | 157 (11.5) | 94 (14.1) | 63 (9.0) | 0.003 |
Proton-pump inhibitor | 3035 (19.5) | 2018 (26.6) | 1017 (12.7) | <0.001 | 245 (17.9) | 168 (25.1) | 77 (11.0) | <0.001 |
Thyroid hormone | 712 (4.6) | 429 (5.7) | 283 (3.5) | <0.001 | 41 (3.0) | 25 (3.7) | 16 (2.3) | 0.115 |
Anticonvulsants | 289 (1.9) | 181 (2.4) | 108 (1.4) | <0.001 | 21 (1.5) | 15 (2.2) | 6 (0.9) | 0.037 |
Immunosuppressants | 953 (6.1) | 587 (7.7) | 366 (4.6) | <0.001 | 51 (3.7) | 29 (4.3) | 22 (3.1) | 0.244 |
Diabetes medications, n (%) | ||||||||
Insulin | 365 (2.3) | 365 (4.8) | - | <0.001 | 29 (2.1) | 29 (4.3) | - | <0.001 |
Metformin | 249 (1.6) | 249 (3.3) | - | <0.001 | 32 (2.3) | 32 (4.8) | - | <0.001 |
Sulfonylurea | 467 (3.0) | 467 (6.2) | - | <0.001 | 50 (3.7) | 50 (7.5) | - | <0.001 |
Alpha-glucosidase inhibitor | 472 (3.0) | 472 (6.2) | - | <0.001 | 48 (3.5) | 48 (7.2) | - | <0.001 |
Thiazolidinedione | 219 (1.4) | 219 (2.9) | - | <0.001 | 25 (1.8) | 25 (3.7) | - | <0.001 |
Resource utilization | ||||||||
BMD test, n (%) | 2251 (14.5) | 913 (12.0) | 1338 (16.8) | <0.001 | 203 (14.9) | 71 (10.6) | 132 (18.9) | <0.001 |
Bone formation test, n (%) | 112 (0.7) | 61 (0.8) | 51 (0.6) | 0.222 | 8 (0.6) | 5 (0.7) | 3 (0.4) | 0.439c |
Bone resorption test, n (%) | 484 (3.1) | 223 (2.9) | 261 (3.3) | 0.237 | 58 (4.2) | 25 (3.7) | 33 (4.7) | 0.370 |
Osteoporosis-related testsd (baseline), n (%) | 3738 (24.0) | 1752 (23.1) | 1986 (24.9) | 0.010 | 323 (23.6) | 133 (19.9) | 190 (27.2) | 0.002 |
Osteoporosis-related testsd (baseline), mean per patient (SD) | 0.421 (0.980) | 0.434 (1.041) | 0.408 (0.918) | 0.098 | 0.358 (0.823) | 0.34 (0.859) | 0.375 (0.788) | 0.433 |
Laboratory tests, n (%) | 1975 (12.7) | 1199 (15.8) | 776 (9.7) | <0.001 | 179 (13.1) | 120 (18.0) | 59 (8.4) | <0.001 |
Laboratory tests, mean per patient (SD) | 8.983 (41.74) | 13.02 (51.36) | 5.144 (29.35) | <0.001 | 7.734 (34.43) | 11.66 (41.1) | 3.986 (26) | <0.001 |
Hospital admissions, n (%) | 1410 (9.1) | 872 (11.5) | 538 (6.7) | <0.001 | 81 (5.9) | 54 (8.1) | 27 (3.9) | <0.001 |
Hospital admissions, mean per patient (SD) | 0.117 (0.47) | 0.147 (0.488) | 0.088 (0.45) | <0.001 | 0.071 (0.313) | 0.099 (0.378) | 0.044 (0.232) | 0.001 |
Days in hospital, mean (SD) | 3.282 (21.65) | 4.33 (27.37) | 2.286 (14.15) | <0.001 | 1.688 (9.911) | 2.147 (11.16) | 1.25 (8.537) | 0.097 |
Outpatient visits, n (%) | 15,297 (98.3) | 7437 (98.1) | 7860 (98.5) | 0.056 | 1353 (99.0) | 660 (98.8) | 693 (99.1) | 0.533 |
Outpatient visits, mean per patient (SD) | 3.567 (8.038) | 4.216 (8.932) | 2.95 (7.03) | <0.001 | 2.52 (3.836) | 2.91 (4.524) | 2.147 (2.992) | <0.001 |
Total cost in JPY, mean (SD) | 122,000 (456,000) | 160,000 (535,000) | 85,215 (361,000) | <0.001 | 60,494 (261,000) | 81,248 (325,000) | 40,661 (178,000) | 0.005 |
Total cost in JPY, median | 13,983 | 18,675 | 10,783 | 9,565 | 13,066 | 6,654 |
Age, fracture and clinical characteristics, and healthcare resource utilization at baseline (overall group)
Age, fracture and clinical characteristics, and healthcare resource utilization at baseline (raloxifene subgroup)
Fracture characteristics and health resource utilization during the follow-up period (overall group)
Unadjusted | Matched | |||||||
---|---|---|---|---|---|---|---|---|
Characteristic | All (N = 15,559) | T2DM (N = 7580) | Non-DM (N = 7979) | P value | All (N = 6546) | T2DM (N = 3273) | Non-DM (N = 3273) | P value |
Fractures | ||||||||
Patients with clinical fracturesa, n (%) | 1882 (12.1) | 1029 (13.6) | 853 (10.7) | <0.001 | 738 (11.3) | 415 (12.7) | 323 (9.9) | <0.001 |
Number of days to first fracture, mean (SD) | 442.8 (259.0) | 443.4 (257.7) | 442.2 (260.6) | <0.0001b | 454.5 (261.8) | 455.5 (259.2) | 453.3 (265.5) | 0.0003b |
Patients with non-vertebral fractures, n (%) | 1454 (9.3) | 817 (10.8) | 637 (8.0) | <0.001 | 565 (8.6) | 329 (10.1) | 236 (7.2) | <0.001 |
Resource utilization | ||||||||
BMD test, n (%) | 6633 (42.6) | 2739 (36.1) | 3894 (48.8) | <0.001 | 2726 (41.6) | 1271 (38.8) | 1455 (44.5) | <0.001 |
Bone formation test, n (%) | 768 (4.9) | 384 (5.1) | 384 (4.8) | 0.466 | 279 (4.3) | 135 (4.1) | 144 (4.4) | 0.582 |
Bone resorption test, n (%) | 1535 (9.9) | 634 (8.4) | 901 (11.3) | <0.001 | 609 (9.3) | 278 (8.5) | 331 (10.1) | 0.024 |
Osteoporosis-related testsc (post-baseline), n (%) | 11,454 (73.6) | 5594 (73.8) | 5860 (73.4) | 0.614 | 4748 (72.5) | 2430 (74.2) | 2318 (70.8) | 0.002 |
Osteoporosis-related testsc (post-baseline), mean per patient (SD) | 2.873 (3.198) | 2.994 (3.369) | 2.758 (3.022) | <0.001 | 2.719 (3.057) | 2.86 (3.118) | 2.578 (2.989) | <0.001 |
Hospital admissions, n (%) | 4799 (30.8) | 2980 (39.3) | 1819 (22.8) | <0.001 | 1941 (29.7) | 1177 (36.0) | 764 (23.3) | <0.001 |
Hospital admissions, mean per patient (SD) | 0.585 (1.451) | 0.776 (1.646) | 0.405 (1.212) | <0.001 | 0.515 (1.46) | 0.635 (1.687) | 0.395 (1.179) | <0.001 |
Days in hospital, mean (SD) | 11.58 (36.23) | 16.02 (44.22) | 7.366 (25.8) | <0.001 | 9.622 (30.03) | 12.33 (34.71) | 6.914 (24.16) | <0.001 |
Outpatient visits, n (%) | 15,511 (99.7) | 7561 (99.7) | 7950 (99.6) | 0.205 | 6529 (99.7) | 3270 (99.9) | 3259 (99.6) | 0.008 |
Outpatient visits, mean per patient (SD) | 39.52 (54.6) | 46.84 (58.98) | 32.56 (49.09) | <0.001 | 36.26 (45.97) | 40.06 (45.13) | 32.45 (46.5) | <0.001 |
Laboratory tests, n (%) | 3010 (19.3) | 1645 (21.7) | 1365 (17.1) | <0.001 | 1338 (20.4) | 762 (23.3) | 576 (17.6) | <0.001 |
Laboratory tests, mean per patient (SD) | 52.11 (182.8) | 68.84 (215.1) | 36.21 (144) | <0.001 | 47.56 (157.9) | 57.57 (167.1) | 37.54 (147.5) | <0.001 |
Total cost in JPY, mean (SD) | 1,130,000 (2,390,000) | 1,490,000 (2,750,000) | 782,000 (1,940,000) | <0.001 | 912,000 (1,860,000) | 1,080,000 (1,930,000) | 743,000 (1,770,000) | <0.001 |
Total cost in JPY, median | 322,000 | 517,000 | 209,000 | 295,000 | 401,000 | 219,000 | <0.001d |
Fracture characteristics and healthcare resource utilization during the follow-up period (raloxifene subgroup)
Unadjusted | Matched | |||||||
---|---|---|---|---|---|---|---|---|
Characteristic | All (N = 1367) | T2DM (N = 668) | Non-DM (N = 699) | P value | All (N = 478) | T2DM (N = 239) | Non-DM (N = 239) | P value |
Fractures | ||||||||
Patients with clinical fracturesa, n (%) | 189 (13.8) | 96 (14.4) | 93 (13.3) | 0.568 | 61 (12.8) | 29 (12.1) | 32 (13.4) | 0.681 |
Number of days to first fracture, mean (SD) | 440.8 (258.9) | 398.2 (250.9) | 484.8 (261) | 0.499b | 423.7 (248.7) | 381.9 (244) | 461.6 (250.6) | 0.717b |
Patients with non-vertebral fractures, n (%) | 148 (10.8) | 79 (11.8) | 69 (9.9) | 0.245 | 51 (10.7) | 24 (10.0) | 27 (11.3) | 0.657 |
Resource utilization | ||||||||
BMD test, n (%) | 634 (46.4) | 239 (35.8) | 395 (56.5) | <0.001 | 232 (48.5) | 96 (40.2) | 136 (56.9) | <0.001 |
Bone formation test, n (%) | 86 (6.3) | 35 (5.2) | 51 (7.3) | 0.117 | 29 (6.1) | 14 (5.9) | 15 (6.3) | 0.848 |
Bone resorption test, n (%) | 157 (11.5) | 60 (9.0) | 97 (13.9) | 0.005 | 54 (11.3) | 26 (10.9) | 28 (11.7) | 0.773 |
Osteoporosis-related testsc (post-baseline), n (%) | 1029 (75.3) | 488 (73.1) | 541 (77.4) | 0.063 | 364 (76.2) | 178 (74.5) | 186 (77.8) | 0.391 |
Osteoporosis-related testsc (post-baseline), mean per patient (SD) | 2.863 (3.031) | 2.867 (3.157) | 2.86 (2.909) | 0.966 | 2.747 (2.698) | 2.816 (2.745) | 2.678 (2.654) | 0.576 |
Hospital admissions, n (%) | 383 (28.0) | 243 (36.4) | 140 (20.0) | <0.001 | 129 (27.0) | 79 (33.1) | 50 (20.9) | 0.003 |
Hospital admissions, mean per patient (SD) | 0.49 (1.053) | 0.668 (1.246) | 0.32 (0.791) | <0.001 | 0.416 (0.849) | 0.49 (0.839) | 0.343 (0.855) | 0.059 |
Days in hospital, mean (SD) | 9.306 (29.13) | 12.69 (35.26) | 6.076 (21.23) | <0.001 | 8.073 (30.44) | 9.586 (34.95) | 6.561 (25.13) | 0.278 |
Outpatient visits, n (%) | 1367 (100.0) | 668 (100.0) | 699 (100.0) | - | 478 (100.0) | 239 (100.0) | 239 (100.0) | - |
Outpatient visits, mean per patient (SD) | 32.72 (38.37) | 38.61 (39.44) | 27.09 (36.47) | <0.001 | 30.59 (34.09) | 31.84 (23.96) | 29.34 (41.85) | 0.424 |
Laboratory tests, n (%) | 268 (19.6) | 162 (24.3) | 106 (15.2) | <0.001 | 88 (18.4) | 55 (23.0) | 33 (13.8) | 0.009 |
Laboratory tests, mean per patient (SD) | 37.93 (127.3) | 50.91 (151.9) | 25.53 (96.77) | <0.001 | 27.54 (79.15) | 36.03 (91.74) | 19.05 (63.21) | 0.019 |
Total cost in JPY, mean (SD) | 750,000 (1,560,000) | 1,010,000 (1,800,000) | 500,000 (1,230,000) | <0.001 | 589,000 (1,170,000) | 665,000 (980,000) | 513,000 (1,340,000) | 0.158 |
Total cost in JPY, median | 240,000 | 396,000 | 144,000 | 215,000 | 314,000 | 150,000 | <0.001d |